Skip to content

Study · Non-randomized trial · n = 9 · 1989

5 results

Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia.

Viganò GL, Mannucci PM, Lattuada A, Harris A, Remuzzi G

American journal of hematology1 May 1989Cited by 21 (Europe PMC)

PMID2705441 (opens in a new tab)DOI10.1002/ajh.2830310106 (opens in a new tab)PepBankPUB-02705441
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In uremic patients, subcutaneous DDAVP significantly shortened bleeding time one hour after administration (P less than .01).

    In plain wordsIn uremic patients, subcutaneous DDAVP shortened bleeding time compared with baseline after one hour.

    Peptide
    Desmopressin
    Outcome
    DecreaseBleeding time at one hour
    Study

    n = 9

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    One hour after administration, the bleeding time was significantly shortened (P less than .01) and became normal in seven of nine patients.
    1 context sentence
    Summary · context
    Since uremic patients experience minor bleeding episodes that might be self-managed at home (particularly epistaxis, gingival bleeding, and menorrhagia), we carried out a double-blind, placebo-controlled crossover study in nine uremics to evaluate whether the prolonged bleeding times could be shorte…
  2. 02HumanNon-randomized trialEfficacy outcome

    In uremic patients, bleeding time became normal in seven of nine patients one hour after subcutaneous DDAVP.

    In plain wordsIn uremic patients, seven of nine had normal bleeding time one hour after subcutaneous DDAVP.

    Peptide
    Desmopressin
    Outcome
    Not applicableNormal bleeding time at one hour
    Study

    n = 9

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Patients with normal bleeding time
    7 patients (of nine)
    one hour after subcutaneous DDAVP

    Source sentences

    Summary
    One hour after administration, the bleeding time was significantly shortened (P less than .01) and became normal in seven of nine patients.
    1 context sentence
    Summary · context
    Since uremic patients experience minor bleeding episodes that might be self-managed at home (particularly epistaxis, gingival bleeding, and menorrhagia), we carried out a double-blind, placebo-controlled crossover study in nine uremics to evaluate whether the prolonged bleeding times could be shorte…
  3. 03HumanNon-randomized trialEfficacy outcome

    In uremic patients, bleeding time remained shorter than baseline four hours after subcutaneous DDAVP (P less than .01).

    In plain wordsIn uremic patients, bleeding time remained shorter than baseline four hours after subcutaneous DDAVP.

    Peptide
    Desmopressin
    Outcome
    DecreaseBleeding time at four hours
    Study

    n = 9

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After 4 hr, the bleeding time was still shorter than baseline (P less than .01), but in only three patients was it still normal.
    1 context sentence
    Summary · context
    Since uremic patients experience minor bleeding episodes that might be self-managed at home (particularly epistaxis, gingival bleeding, and menorrhagia), we carried out a double-blind, placebo-controlled crossover study in nine uremics to evaluate whether the prolonged bleeding times could be shorte…
  4. 04HumanNon-randomized trialEfficacy outcome

    In uremic patients, bleeding time remained normal in three patients four hours after subcutaneous DDAVP.

    In plain wordsIn uremic patients, three patients retained normal bleeding time four hours after subcutaneous DDAVP.

    Peptide
    Desmopressin
    Outcome
    Not applicableNormal bleeding time at four hours
    Study

    n = 9

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Patients with normal bleeding time
    3 patients (of nine)
    four hours after subcutaneous DDAVP

    Source sentences

    Summary
    After 4 hr, the bleeding time was still shorter than baseline (P less than .01), but in only three patients was it still normal.
    1 context sentence
    Summary · context
    Since uremic patients experience minor bleeding episodes that might be self-managed at home (particularly epistaxis, gingival bleeding, and menorrhagia), we carried out a double-blind, placebo-controlled crossover study in nine uremics to evaluate whether the prolonged bleeding times could be shorte…
  5. 05HumanNon-randomized trialEfficacy outcome

    In uremic patients, bleeding times did not differ significantly after equal doses of subcutaneous and intravenous DDAVP.

    In plain wordsIn uremic patients, bleeding times did not differ significantly between subcutaneous and intravenous DDAVP.

    Peptide
    Desmopressin
    Outcome
    No significant changeBleeding time by administration route
    Study

    n = 9

    Comparator
    Same dose intravenously
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneous and intravenousAs given in this study (human).

    Source sentences

    Summary
    When the same patients were treated with the same dose of DDAVP infused intravenously, the bleeding times were not significantly different from those measured after subcutaneous administration.
    1 context sentence
    Summary · context
    Since uremic patients experience minor bleeding episodes that might be self-managed at home (particularly epistaxis, gingival bleeding, and menorrhagia), we carried out a double-blind, placebo-controlled crossover study in nine uremics to evaluate whether the prolonged bleeding times could be shorte…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.